Monolithic maleic anhydride drug delivery systems
First Claim
Patent Images
1. An erodible, self-lubricating, bio-adhesive drug delivery vehicle consisting essentially of:
- homogeneous poly(methylvinylether/maleic anhydride) copolymer; and
from approximately 1% to 60% by weight therapeutic or diagnostic pharmaceutical compound incorporated therein, wherein said vehicle erodes by hydrolysis of the maleic anhydride units to provide two carboxylic radicals for each maleic anhydride unit and said copolymer has a ratio of carbon atoms to carboxylic radicals of about 3.5.
2 Assignments
0 Petitions
Accused Products
Abstract
Erodible bioadhesive drug delivery vehicles for use in delivering pharmaceutical compounds to the eye and similar physiological environments are disclosed. The drug delivery vehicles are formed of a homopolymer or copolymer of maleic anhydride or lower alkyl maleic anhydride incorporating a pharmaceutical compound in either a monolithic matrix or encapsulated form. The bioadhesive erodible drug delivery vehicles are configured to be retained in the eye following administration while providing specific erosion profiles allowing convenient drug delivery schedules ranging from hourly to daily or weekly intervals.
40 Citations
36 Claims
-
1. An erodible, self-lubricating, bio-adhesive drug delivery vehicle consisting essentially of:
-
homogeneous poly(methylvinylether/maleic anhydride) copolymer; and from approximately 1% to 60% by weight therapeutic or diagnostic pharmaceutical compound incorporated therein, wherein said vehicle erodes by hydrolysis of the maleic anhydride units to provide two carboxylic radicals for each maleic anhydride unit and said copolymer has a ratio of carbon atoms to carboxylic radicals of about 3.5. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method for delivering a pharmaceutical compound to the eye, said method comprising the steps of:
-
preparing an erodible, self-lubricating, self-adhesive, bio-adhesive monolithic matrix consisting essentially of homogeneous poly(methylvinylether/maleic anhydride) copolymer and a pharmaceutically an effective concentration of at least one pharmaceutical compound; and introducing said monolithic matrix into the conjunctival sac of the eye, wherein said copolymer erodes by hydrolysis of the maleic anhydride units to provide two carboxylic radicals for each maleic anhydride unit and said copolymer has a ratio of carbon atoms to carboxylic radicals of about 3.5. - View Dependent Claims (19, 20)
-
-
21. An erodible, self-lubricating, bio-adhesive drug delivery vehicle consisting essentially of:
-
a lower alkyl maleic anhydride or maleic anhydride homogeneous copolymer of the formula ##STR4## wherein R1 is C1-4 alkyl, alkylether, alkylester, or halogen;
R2 and R3 are each selected from the group consisting hydrogen and C1-4 ; andfrom approximately 1% to 60% by weight therapeutic or diagnostic pharmaceutical compound incorporated therein, wherein said vehicle erodes by hydrolysis of the maleic anhydride or lower alkyl maleic anhydride units to provide two carboxylic radicals for each maleic anhydride unit and said copolymer has a ratio of carbon atoms to carboxylic radicals ranging from about 3 to 7.
-
-
22. An erodible, self-lubricating, bio-adhesive drug delivery vehicle consisting essentially of:
-
a maleic anhydride or a lower alkyl maleic anhydride homogeneous homopolymer or copolymer; and from approximately 1% to 60% by weight therapeutic or diagnostic pharmaceutical compound incorporated therein, wherein said vehicle erodes by hydrolysis of the maleic anhydride or lower alkyl maleic anhydride units to provide two carboxylic radicals for each anhydride unit and said polymer has a ratio of carbon atoms to carboxylic radicals ranging from 2 to 7. - View Dependent Claims (23, 24, 25, 26, 32, 33, 34, 35, 36)
-
-
27. A method for delivering a pharmaceutical compound to the eye, said method comprising the steps of:
-
preparing an erodible, self-lubricating, self-adhesive, bio-adhesive monolithic matrix consisting essentially of a maleic anhydride or a lower alkyl maleic anhydride homogeneous homopolyer or copolymer and a pharmaceutically effective concentration of at least one pharmaceutical compound; and introducing said monolithic matrix into the conjunctival sac of the eye, wherein said matrix erodes by hydrolysis of the maleic anhydride or lower alkyl maleic anhydride units to provide two carboxylic radicals for each anhydride unit and said polymer has a ratio of carbon atoms to carboxylic radicals from 2 to 7. - View Dependent Claims (28, 29, 30, 31)
-
Specification